Becton, Dickinson and Company Overview
Company Headquarters: New Jersey, US
Founded: 1897
Workforce: ~65,000
Company Working: Becton, Dickinson and Company (BD) is engaged in developing and manufacturing medical supplies, laboratory equipment, and diagnostic products. It operates in two segments, BD Medical and BD Life Sciences. Its life sciences segment offers products, such as liquid-based cytology systems, specimens, and blood collection products and systems, automated blood and tuberculosis culturing, molecular testing, rapid diagnostic assays, microbiology laboratory automation products, and fluorescence-activated cell sorters. Its medical segment comprises products, such as needle-free IV connectors and extension sets, peripheral IV and advanced peripheral catheters, acute dialysis catheters, vascular care and preparation products, and IV fluids.
BD has a strong presence throughout Eastern Europe, the Middle East, and Africa regions with technical specialists, sales specialists, technical service, and application support for its products. The company distributes its products in North America (Canada, Mexico, and the US), Europe (Belgium, Denmark, Finland, France, Germany, Ireland, Italy, Netherland, Poland, Switzerland, Russia, United Kingdom, Turkey, Hungary, Italy), South America (Argentina, Brazil, Chile, and Colombia), Asia-Pacific (Australia, New Zealand, Indonesia, Korea, Malaysia, Philippines, Thailand, and Vietnam) and the Middle East and Africa (the Middle East, North Africa, and Africa).
Strategy
Becton, Dickinson and Company focuses to achieve growth by expanding its product portfolio and geographic reach through both organic growth and acquisitions. The company is investing heavily in research and development to develop new products and technologies that can improve patient outcomes and reduce healthcare costs. In addition, Becton, Dickinson and Company is focused on expanding its market share in emerging markets with increasing healthcare needs, such as Asia and Latin America. The company is also pursuing strategic partnerships and collaborations to leverage complementary capabilities and expand its market reach, with a focus on expanding its presence in the oncology and immunology spaces.



